Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Chinese startups can develop digital avatars almost as good as human streamers using just a few minutes of footage, noted ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, will be hosting Pharma.AI Week featuring in-depth webinar series from November ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Insilico rose to prominence in 2019 after it published a Nature Biotechnology paper detailing how its research team developed, synthesised, and validated a novel drug candidate in just 46 days.

Hong Kong-based Insilico Medicine has begun a Phase 1 trial of its AI-discovered and AI-designed anti-fibrotic small molecule inhibitor. Currently referred to as ISM001-055, the drug is meant to ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.